

## Aldeyra Therapeutics Schedules Webcast and Conference Call to Report Second-Quarter 2021 Financial Results and Discuss Recent Business Highlights

July 29, 2021

LEXINGTON, Mass.--(BUSINESS WIRE)--Jul. 29, 2021-- Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra) will host a conference call at 8:00 a.m. ET Thursday, August 5, 2021 to report financial results for the quarter ended June 30, 2021 and discuss recent business highlights.

The dial-in numbers are (866) 211-4098 for domestic callers and (647) 689-6613 for international callers. The Conference ID number is 4968588. A live webcast of the conference call will also be available on the Investors & Media page of the company's corporate website at <a href="https://ir.aldevra.com">https://ir.aldevra.com</a>.

After the live webcast, the event will remain archived on the Aldeyra Therapeutics website for 90 days.

## About Aldeyra Therapeutics, Inc.

Aldeyra Therapeutics is a biotechnology company developing novel immune-modulating therapies to treat ocular and systemic diseases. Two of the company's lead product candidates, reproxalap and ADX-629, target RASP, which are pre-cytokine, systems-based mediators of inflammation. Reproxalap is being evaluated in Phase 3 clinical trials in patients with dry eye disease and allergic conjunctivitis. The company's clinical pipeline also includes ADX-2191 (methotrexate for intravitreal injection), a drug candidate in Phase 3 testing for the prevention of proliferative vitreoretinopathy. For more information, visit <a href="https://www.aldeyra.com/">https://www.aldeyra.com/</a> and follow us on <a href="https://www.aldeyra.com/">LinkedIn</a>, <a href="https://www.aldeyra.com/">Eacebook</a>, and <a href="https://www.aldeyra.com/">Twitter</a>.

View source version on businesswire.com: https://www.businesswire.com/news/home/20210729005551/en/

## **Corporate Contact:**

Joshua Reed Aldeyra Therapeutics, Inc. Tel: 781-761-4904 ext. 218 ireed@aldeyra.com

## **Investor & Media Contact:**

Scott Solomon Sharon Merrill Associates, Inc. Tel: 617-542-5300 ALDX@investorrelations.com

Source: Aldeyra Therapeutics, Inc.